Trialbee hires senior executives from the pharma industry

Swedish e-clinical solutions developer hires former H. Lundbeck and Bristol-Myers Squibb executives to Board

Trialbee, a Swedish developer of software for use in clinical trials, has appointed Ulf Wiinberg, formerly Chief Executive of H. Lundbeck, as Chairman of the Board.

Lars Birgerson, who was recently Senior Vice President, Medical R&D at Bristol-Myers Squibb, has also become a member of the board.

These appointments bring a wealth of expertise from the life science industry and medical world to the firm as it prepares to expand into new market segments.

Wiinberg brings 30 years of experience from the pharmaceutical industry to the company.

He said Trialbee's mission to digitise the clinical trial process 'has the potential to transform the pharmaceutical industry'.

'With my background I clearly see the value Trialbee can bring. I decided to join the board to be part of the journey from start-up to global brand.'

Birgerson brings extensive knowledge of drug development, medical affairs, health economics and outcomes research.

'Trialbee's solution provides a great opportunity to connect patients and clinical research,' he said.

'Empowering patients is key to secure successful outcomes in the digital era. I'm honoured to bring my expertise and international network to help facilitate this transformation, improving the development of new and better treatments to help patients.'

You may also like

Regulatory

Overcoming CMC challenges in cell and gene therapy: part I

Certara’s Dr Hien Anh Bruno, Associate Director, Chemistry, Manufacturing and Controls (CMC), and Dr Deven Shah, CMC Lead, propose mitigation strategies to address the CMC challenges inherent in producing cell and gene therapy (CGT) drugs
Regulatory

AskBio receives FDA Fast Track Designation for congestive heart failure gene therapy programme

The fast-tracking allows the development and expedition of review processes for AB-1002, a gene therapy to promote production of a constituently active form of I-1c
Manufacturing

Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success

Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for successful market entry from the early stages of development, reports Frederick Duynslaeger, Senior CMC Writer at Ardena
Regulatory

Isospec Analytics launches biomolecular analysis technology to identify unknown molecules

The novel technology optimises the identification process of unknown molecules compared to mass analysis
Regulatory

4SC AG receives Paediatric Investigation Plan waiver for resminostat from the UK MHRA

The waiver allows the company to avoid investigating the CTCL drug in a paediatric population, as it's considered unnecessary or inappropriate for use by this patient group
Regulatory

The key role of IVDs in healthcare: challenges to commercialisation and access

In simple terms, in vitro diagnostic (IVD) tests are done on samples such as blood or tissue that have been taken from the human body. IVDs can detect diseases, conditions and infections, provide patients with a better understanding of their ailment and how it might be managed and changed with treatment
Regulatory

Post-Brexit border paperwork and inspections postponed for life sciences sector

The six month extension will allow life science companies to the make necessary alterations to their supply chains to accommodate for the novel post-Brexit border paperwork
Subscribe now